Extremely High Objective Response Rate of Lenvatinib: Its Clinical Relevance and Changing the Treatment Paradigm in Hepatocellular Carcinoma | Semantic Scholar
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM
Efficacy endpoints in Oncology
Forest plot of the comparison of overall response rate (ORR).
Overall Response Rates - WM | IMBRUVICA® (ibrutinib) HCP
ORR (Objective Response Rate) and related statistics – Part 1
COTELLIC® (cobimetinib) + ZELBORAF® (vemurafenib) Objective Response Rate
Durable Response Rate
Visualization of efficacy endpoints in oncology clinical trials
Overall Response Rate | CALQUENCE® (acalabrutinib) 100 mg tablets | For HCPs
Nexcella Announces Positive 58-Patient NXC- 201 Clinical Data: 100% Overall Response Rate in light chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris | BioSpace
Comparing Outcomes in Patients with Recurrent or Refractory Ovarian Cancer Managed with 1 of 2 Versions of Pegylated Liposomal Doxorubicin at an Academic Medical Center
Predicting Successful Phase Advancement and Regulatory Approval in Multiple Myeloma From Phase I Overall Response Rates | JCO Clinical Cancer Informatics
Overall response rate | Download Table
Best Overall Response Rate (full analysis population) | Download Table
Efficacy - Overall Response Rate | Aliqopa US HCP
What Low Response Rates Mean for Telephone Surveys | Pew Research Center
Efficacy I PLUVICTO
Durable Response Rate
Efficacy | Tivdak® (tisotumab vedotin-tftv)
Overall Response Rate of 76% in Advanced Melanoma Patients with Dynavax's SD-101 in Combination with KEYTRUDA® (pembrolizumab); Data Presented Today at the 2019 ASCO Annual Meeting | Dynavax Technologies Corporation
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial | Nature Medicine
Efficacy | BALVERSA® (erdafitinib) HCP
Updated Data for Indoximod Plus KEYTRUDA® (pembrolizumab) Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma | Business Wire
RESONATE-2 - Overall Response Rate | IMBRUVICA® (ibrutinib) HCP
Response rates Overall response rate and depth of response according to... | Download Scientific Diagram
